Targeting the duality of cancer
Open Access
- 21 June 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in npj Precision Oncology
- Vol. 1 (1), 1-7
- https://doi.org/10.1038/s41698-017-0026-x
Abstract
Cancer is the second leading cause of death in the United States, and is an increasing cause of death in the developing world. While there is great heterogeneity in the anatomic site and mutations involved in human cancer, there are common features, including immortal growth, angiogenesis, apoptosis evasion, and other features, that are common to most if not all cancers. However, new features of human cancers have been found as a result of clinical use of novel "targeted therapies," angiogenesis inhibitors, and immunotherapies, including checkpoint inhibitors. These findings indicate that cancer is a moving target, which can change signaling and metabolic features based upon the therapies offered. It is well-known that there is significant heterogeneity within a tumor and it is possible that treatment might reduce the heterogeneity as a tumor adapts to therapy and, thus, a tumor might be synchronized, even if there is no major clinical response. Understanding this concept is important, as concurrent and sequential therapies might lead to improved tumor responses and cures. We posit that the repertoire of tumor responses is both predictable and limited, thus giving hope that eventually we can be more effective against solid tumors. Currently, among solid tumors, we observe a response of 1/3 of tumors to immunotherapy, perhaps less to angiogenesis inhibition, a varied response to targeted therapies, with relapse and resistance being the rule, and a large fraction being insensitive to all of these therapies, thus requiring the older therapies of chemotherapy, surgery, and radiation. Tumor phenotypes can be seen as a continuum between binary extremes, which will be discussed further. The biology of cancer is undoubtedly more complex than duality, but thinking of cancer as a duality may help scientists and oncologists discover optimal treatments that can be given either simultaneously or sequentially.This publication has 98 references indexed in Scilit:
- Macropinocytosis of protein is an amino acid supply route in Ras-transformed cellsNature, 2013
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaNature Genetics, 2012
- Beta-catenin inhibits melanocyte migration but induces melanoma metastasisOncogene, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Inhibition of mitochondrial fission prevents cell cycle progression in lung cancerThe FASEB Journal, 2012
- High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial CancerCancer Research, 2010
- Rac Activation and Inactivation Control Plasticity of Tumor Cell MovementCell, 2008
- A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- K-ras Mutation and p16 and Preproenkephalin Promoter Hypermethylation in Plasma DNA of Pancreatic Cancer PatientsPancreas, 2007
- Sentinel-Node Biopsy or Nodal Observation in MelanomaThe New England Journal of Medicine, 2006